Actively Recruiting

Phase Not Applicable
Age: 18Years - 65Years
All Genders
ID07304778

Evaluation of a Mobile AI-powered Decision Support System for Insulin Dosing and Glucose Prediction in Type 1 Diabetes: The glUCModel Clinical Trial Protocol

Led by Universidad Complutense de Madrid · Updated on 2026-01-06

34

Participants Needed

2

Research Sites

17 weeks

Total Duration

On this page

Sponsors

U

Universidad Complutense de Madrid

Lead Sponsor

B

Bioinspired Intelligence SL

Collaborating Sponsor

AI-Summary

What this Trial Is About

This research aims to evaluate the safety and effectiveness of integrating predictive models into insulin therapy management through the glUCModel mobile app in adults with Type 1 Diabetes Mellitus who are using Multiple Daily Injections (MDI) therapy. The study focuses on whether using the app improves blood sugar control by increasing the time glucose levels stay within a target range, reducing episodes of high and low blood sugar, and assessing the app's design and usability. The trial is a randomized and open-label study involving participants aged 18 to 65 years. Participants will go through four phases: an initial screening phase to collect consent and baseline data; a 2-week run-in phase where standard care with continuous glucose monitoring (CGM) is followed to create personalized models for those in the app group; an active treatment phase where all continue MDI therapy with the intervention group additionally using the glUCModel app; and a final evaluation phase involving questionnaires and data analysis. CGM data from the last two weeks of treatment will be analyzed to measure outcomes. During the study, participants will complete questionnaires assessing treatment satisfaction and usability, including the Pittsburgh and DTSQ surveys. Researchers will monitor blood sugar levels, counting the frequency and duration of hypo- and hyperglycemic events, glycemic variability, and adherence to app recommendations. The primary outcome is the percentage of time spent in the target glucose range during the last two weeks. The total participation spans from screening through data evaluation, with safety and usability closely monitored throughout.

CONDITIONS

Brief Title

Evaluation of a Mobile AI-powered Decision Support System for Insulin Dosing and Glucose Prediction in Type 1 Diabetes: The glUCModel Clinical Trial Protocol

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • HbA1c less than 9%
  • Currently following multiple daily injections (MDI) bolus-basal insulin therapy
  • Wearing continuous glucose monitors (CGMs) connected to a mobile phone
  • Proficient in Spanish language
  • Willing to participate in the trial
  • At least one year since diabetes diagnosis
  • Able to use a mobile application like glUCModel
  • Own a mobile phone with Android or iOS operating system
  • Able to follow a portion-controlled diet for diabetes
  • Educated to actively manage insulin dosing
Not Eligible

You will not qualify if you...

  • HbA1c 9% or higher
  • Not wearing continuous glucose monitors (CGMs)
  • Not proficient in Spanish language
  • Less than one year since diabetes diagnosis
  • Unable to use a mobile application like glUCModel
  • Unable to follow a portion-controlled diet for diabetes
  • Unable to actively manage insulin dosing
  • Diagnosed with a significant psychiatric disorder
  • Currently treated with corticosteroids
  • Hospitalized or had surgery in the last six months
  • Pregnant or planning pregnancy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 screening and enrollment visit

Treatment

Duration - 2 weeks

Participants continue their multiple daily injection insulin therapy. Those in the intervention group will also use the glUCModel mobile application to receive AI-powered insulin dosing recommendations and glucose predictions.

Regular use of the mobile app during the treatment period; visit frequency as per standard clinical care

Trial Site Locations

Total: 2 locations

1

Universidad Complutense de Madrid

Madrid, Madrid, Spain, 280240

Not Yet Recruiting

2

Hospital Universitario de Toledo

Toledo, Toledo, Spain, 45007

Actively Recruiting

Loading map...

Research Team

I

Ignacio Hidalgo, PhD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

HEALTH_SERVICES_RESEARCH

Number of Arms

2

Similar Trials

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here